Antiretroviral medications
Phase 3Small molecule
Antiretroviral medications is one of 71 small molecule programs targeting HIV infection. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
326 competitors in HIV Infection
#DrugCompanyPhaseTrials
1Leukine
SanofiPhase 3
Intron a
Merck & Co.Phase 3
Betaseron
BayerPhase 3
Megace
Bristol-Myers SquibbPhase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Proleukin
IIovance Biotherapeutics, Inc.
Phase 3
Foscavir
NNational Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
TWINRIX™
GSKPhase 3
PTM SEMA
GileadPhase 3
F/TAF
GileadPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
HIV infection1 trial
Multicentric Trial Comparing Three Therapeutical Strategies in Patients With Acute Primary HIV Infection
Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2/3·NCT00196638·90 enrolled
Tuberculosis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Antiretroviral medications. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details